PROTECTIVE Trials of Plinabulin in Solid Tumors
An overview of the Protective-1 trial of single-agent plinabulin vs pegfilgrastim after docetaxel in patients with advanced breast cancer, advanced non–small cell lung cancer, and hormone-refractory prostate cancer.
Plinabulin for CIN
The rationale for studying plinabulin, a first-in-class selective immunomodulating microtubule binding agent, for the prevention of chemotherapy-induced neutropenia.
CIN and Metastatic Disease
Strategies for prophylaxis against chemotherapy-induced neutropenia in the setting of metastatic disease.
Challenges Managing CIN
Limitations of current therapies available for the prevention and management of chemotherapy-induced neutropenia.
Treatment Options for CIN
Current mitigation and management strategies for chemotherapy-induced neutropenia.
Future Directions for Myelofibrosis Treatment
John Mascarenhas, MD, and Ruben Mesa, MD, share insights on the evolving treatment landscape of myelofibrosis.
Minimizing the Risk of CIN in the Curative Setting
Recommendations for preventing and mitigation infection risk in patients with chemotherapy-induced neutropenia in the adjuvant setting.
CIN Severity and Management
Implications of severity and sequelae of chemotherapy-induced neutropenia for disease management.
Future Directions in Advanced Urothelial Carcinoma
Drs Neeraj Agarwal and Petros Grivas comment on biomarkers and novel therapies under investigation for advanced urothelial carcinoma and remark on the next steps for treating patients with antibody-drug conjugates.
Using JAK Inhibitors for the Treatment of Myelofibrosis
Expert hematologist-oncologists comment on the optimization of JAK inhibitor therapies, including ruxolitinib, momelotinib, fedratinib, and pacritinib, in myelofibrosis treatment.
Optimizing Therapy for Patients With Advanced Urothelial Carcinoma
Strategies to help manage treatment-related toxicities to novel therapies used in the management of advanced urothelial carcinoma.
Key Clinical Trials in Myelofibrosis
Drs Ruben Mesa and John Mascarenhas review therapies and drugs in development for the treatment of myelofibrosis as seen in the COMFORT, JAKARTA, MOMENTUM, PACIFICA, and PERSIST trials.
Patient-Reported Outcomes in Advanced Urothelial Carcinoma
The importance of collecting patient-reported outcomes data in urothelial carcinoma as it relates to novel treatment selection.
CIN Prophylaxis in Solid Tumors
Considerations for treatment selection for chemotherapy-induced neutropenia.
CIN in Solid Tumors
General considerations surrounding the risk of chemotherapy-induced neutropenia in solid tumors.
Role of IRAK Signaling in Myelofibrosis
John Mascarenhas, MD, and Ruben Mesa, MD, share insights on the role of IRAK signaling on the disease biology of myelofibrosis.
ADCs for Urothelial Carcinoma: Selection and AE Management
Advice regarding patient selection for sacituzumab govitecan and the management of treatment-related adverse events.
Novel Sequencing Strategies for Advanced Urothelial Carcinoma
Recommendations regarding how to best integrate newer therapies, including antibody-drug conjugates, into treatment plans for patients with advanced urothelial carcinoma.
Targeting JAK2 in Myelofibrosis
Hematology/oncology experts review the role of JAK2 allele burden in patients and its effect on treatment outcomes for myelofibrosis.
Trop-2–Targeting ADC Therapy for Advanced Urothelial Carcinoma
The rationale for treating patients with advanced urothelial carcinoma with sacituzumab govitecan, a novel antibody-drug conjugate now approved that targets Trop-2.
Improving Survival Rates in Myelofibrosis
Ruben Mesa, MD, and John Mascarenhas, MD, discuss whether therapies with a clinically meaningful impact on myelofibrosis may have a survival advantage for patients.
Goals of Therapy: Reversing Bone Marrow Fibrosis
Expert hematologist/oncologists comment on the value of reducing fibrosis as a potential goal of therapy when treating patients with myelofibrosis.
Antibody-Drug Conjugates in Advanced Urothelial Carcinoma
Reactions to the availability of antibody-drug conjugates as later-line therapy for patients with metastatic urothelial carcinoma, and potential considerations for adopting enfortumab vedotin into clinical practice.
Challenges of Treating Myelofibrosis
Drs John Mascarenhas and Ruben Mesa review unmet needs and challenges in treating myelofibrosis.
Second-Line Treatment for Metastatic Urothelial Carcinoma
Second-line treatment approaches available for metastatic urothelial carcinoma and considerations for switching therapies vs re-challenging with prior therapy.
Molecular Testing in Metastatic Urothelial Carcinoma
What to know regarding molecular testing assays used to assess patients with metastatic urothelial carcinoma.
Role of Molecular Testing in Myelofibrosis Treatment
Ruben Mesa, MD, and John Mascarenhas, MD, review the patient selection of extended molecular panels and the appropriate interval for molecular profiling for the management of myelofibrosis.
Future Directions in the Treatment of DLBCL
Loretta Nastoupil, MD, and John Burke, MD, discuss the future of the therapeutic landscape for patients with transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma.
Findings From the LOTIS-2 Trial: Loncastuximab Tesirine
Experts discuss the LOTIS-2 trial that studied loncastuximab tesirine, a CD19-targeted monoclonal antibody for treating patients with relapsed/refractory diffuse large B-cell lymphoma.
Frontline Treatment for Metastatic Urothelial Carcinoma
First-line treatment options available for patients with metastatic urothelial carcinoma and variables that impact treatment selection.